Increasing telithromycin resistance among Streptococcus pyogenes in Europe

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 603-611

  Richter, Sandra S ^a   Heilmann, Kristopher P ^a   Dohrn, Cassie L ^a   Beekmann, Susan E ^a   Riahi, Fathollah ^a   Garcia de Lomas, Juan ^b   Ferech, Matus ^c   Goossens, Herman ^c   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Instituto Valenciano de Microbiologia   (Spain)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Group A streptococci; Ketolides; Macrolides

Indexed keywords

AZITHROMYCIN; CEFDINIR; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG USE; EUROPE; GENE IDENTIFICATION; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS PYOGENES;

DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; KETOLIDES; PROTEIN SYNTHESIS INHIBITORS; RNA, RIBOSOMAL, 23S; STREPTOCOCCUS PYOGENES;

EID: 40049096152     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm525     Document Type: Article

References (44)

1. Beekmann SE, Heilmann KP, Richter SS et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streptococci in 2002-03. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 2005; 25: 148-56.
2. Kim S, Yong Lee N. Epidemiology and antibiotic resistance of group A streptococci isolated from healthy schoolchildren in Korea. J Antimicrob Chemother 2004; 54: 447-50.
3. Hsueh P-R, Chen H-M, Huang A-H et al. Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995; 39: 2239-42.
4. Bandak SI, Tumak MR, Allen BS et al. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries. Int J Clin Prac 2000; 54: 585-8.
5. Baquero F, Garcia-Rodriguez JA, De Lomas JG et al. Antimicrobial resistance of 914 β-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999; 43: 178- 80.
6. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs 1996; 51 Suppl 1: 20-30.
7. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and S. pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.
8. Seppala H, Skurnik M, Soini H et al. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42: 257-62.
9. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-92.
10. Tanz RR, Shulman ST, Shortridge VD et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis 2004; 39: 1794-801.
11. Malbruny B, Nagai K, Coquemont M et al. Resistance to macrolides in clinical isolates of Strepfococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother 2002; 49: 935-9.
12. Bingen E, Leclercq R, Fitoussi F et al. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002; 46: 199-203.
13. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623-31.
14. Jalava J, Kataja J, Seppala H et al. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001; 45: 789-93.
15. Lonks JR, Goldmann DA. Telithromycin: A ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005; 40: 1657-64.
16. Bemer-Melchior P, Juvin ME, Tassin S et al. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: Influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 2000; 44 2999-3002.
17. Reinert RR, Lutticken R, Sutcliffe JA et al. Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother 2004; 48: 1369-73.
18. Nagai K, Applebaum PC, Davies TA et al. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and eastern European countries. Antimicrob Agents Chemother 2002; 46: 546-9.
19. Ruoff KL, Wiley RA, Beighton D. Streptococcus. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of Clinical Microbiology, 8th edn, vol. 1. Washington, DC: ASM Press, 2003; 409.
20. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
22. Vander Stichele R, Elseviers M, Ferech M et al. European Surveillance of Antimicrobial Consumption (ESAC): Data collection performance and methodological approach. Br J Clin Pharmacol 2004; 58: 419-28.
23. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58: 401-7.
24. Coenen S, Ferech M, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 2006; 58: 418-22.
25. Sutcliffe J, Grebe T, Tait-Kamradt A et al. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40: 2562-6.
26. Bingen E, Fitoussi F, Doit C et al. Resistance to macrolides Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 2000; 44: 1453-7.
27. Richter SS, Heilmann KP, Beekmann SE et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41: 599-608.
28. Tait-Kamradt A, Davies T, Cronan M et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrobiol Agents Chemother 2000; 44: 2118-25.
29. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33 2233-9.
30. Tamayo J, Perez-Trallero E, Gomez-Garces JL et al. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother 2005; 56: 780-2.
31. Cornaglia G, Ligozzi M, Mazzariol A et al. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. Clin Infect Dis 1998; 27 Suppl 1: S87-92.
32. Dicuonzo G, Fiscarelli E, Gherardi G et al. Erythomycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy. Antimicrob Agents Chemother 2002; 46: 3987-90.
33. Yi YH, Choi JH, Lee HK et al. Characterization of erythromycin resistance of Streptococcus pyogenes isolated from pharyngitis patients in Korea. Jpn J Infect Dis 2006; 59: 192-4.
34. Farrell DJ, Morrissey I, Bakker S et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolates from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 56 Suppl 1: 39-47.
35. Grivea IN, Al-Lahham A, Katopodis GD et al. Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: Phenotypic and genotypic analysis. Antimicrob Agents Chemother 2006; 50: 256-61.
36. Malhotra-Kumar S, Lammens C, Chapelle S et al. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Emerg Infect Dis 2005; 11: 939-42.
37. Weisblum B. Erythromycin resistance by ribosomal methylation. Antimicrob Agents Chemother 1995; 39: 577-85.
38. Douthwaite S, Jalava J, Jakobsen L. Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol Microbiol 2005; 58: 613-22.
39. Butler JC, Lennox JL, McDougal LK et al. Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis 2003; 36: E19-25.
40. Farrell DJ, Shackcloth J, Barbadora KA et al. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother 2006; 50: 817-8.
41. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Eng J Med 1997; 337: 441-6.
42. Granizo JJ, Aguilar L, Casal J et al. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000; 46: 959-64.
43. Gagliotti C, Nobilio L, Milandri M et al. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes. Clin Infect Dis 2006; 42: 1153-6.
44. Malhotra-Kumar S, Lammens C, Coenen S et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers; a randomized, double-blind, placebo-controlled study. Lancet 2007; 369: 482-90.